Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula

Peptides

Volumn 28, Issue 8, 2007, Pages 1483-1489

  Harris, Gregory S ^a   Lust, Robert M ^a   Katwa, Laxmansa C ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Congestive heart failure; Hemodynamic function; Urotensin II; Volume overload

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CALCIUM ION; NEUROPEPTIDE RECEPTOR; PHOSPHOLAMBAN; REGULATOR PROTEIN; SARCOPLASMIC RETICULUM CALCIUM ATPASE 2; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTOCAVAL FISTULA; ARTICLE; CALCIUM SIGNALING; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; HEMODYNAMICS; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SARCOPLASMIC RETICULUM;

ANIMALS; AORTIC DISEASES; ARTERIOVENOUS FISTULA; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; HEART FAILURE, CONGESTIVE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; MALE; MYOSIN HEAVY CHAINS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-CALCIUM EXCHANGER; UROTENSINS; VENAE CAVAE; VENTRICULAR FUNCTION, LEFT;

ANIMALIA; FISTULA;

EID: 34547885837     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.04.018     Document Type: Article

References (30)

1. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 1 (2004) 117-123
2. Camarda V., Song W., Marzola E., Spagnol M., Guerrini R., Salvadori S., et al. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 498 1-3 (2004) 83-86
3. Cantor E.J., Babick A.P., Vasanji Z., Dhalla N.S., and Netticadan T. A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. J Mol Cell Cardiol 38 5 (2005) 777-786
4. Conlon J.M., Yano K., Waugh D., and Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 275 2-3 (1996) 226-238
5. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 9322 (2002) 1990-1997
6. Dschietzig T., Bartsch C., Pregla R., Zurbrugg H.R., Armbruster F.P., Richter C., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110 1 (2002) 33-38
7. Filipeanu C.M., Brailoiu E., Le Dun S., and Dun N.J. Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons. J Neurochem 83 4 (2002) 879-884
8. Garcia R., and Diebold S. Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res 24 5 (1990) 430-432
9. Gruson D., Rousseau M.F., Ahn S.A., van Linden F., and Ketelslegers J.M. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27 6 (2006) 1527-1531
10. Haghighi K., Gregory K.N., and Kranias E.G. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 322 4 (2004) 1214-1222
11. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
12. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 4 (2004) 238-250
13. Joyal D., Huynh T., Aiyar N., Guida B., Douglas S., and Giaid A. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 108 1 (2006) 31-35
14. Kompa A.R., Thomas W.G., See F., Tzanidis A., Hannan R.D., and Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 25 10 (2004) 1783-1788
15. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 1 (2004) 93-97
16. Lim M., Honisett S., Sparkes C.D., Komesaroff P., Kompa A., and Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109 10 (2004) 1212-1214
17. Nakanishi K., Nakata Y., Kanazawa F., Imamura S., Matsuoka R., Osada H., et al. Changes in myosin heavy chain and its localization in rat heart in association with hypobaric hypoxia-induced pulmonary hypertension. J Pathol 197 3 (2002) 380-387
18. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 23 (2002) 2877-2880
19. Ong K.L., Lam K.S., and Cheung B.M. Urotensin II: its function in health and its role in disease. Cardiovasc Drugs Ther 19 1 (2005) 65-75
20. Qvigstad E., Sjaastad I., Brattelid T., Nunn C., Swift F., Birkeland J.A.K., et al. Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart. Circ Res 97 3 (2005) 268-276
21. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 9332 (2002) 545-546
22. Russell F.D. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 103 3 (2004) 223-243
23. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 4 (2003) H1576-H1581
24. Russell F.D., and Molenaar P. Cardiovascular actions of human urotensin II-considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol 369 3 (2004) 271-273
25. Russell F.D., and Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 63 4 (2004) 673-681
26. Sondermeijer B., Kompa A., Komesaroff P., and Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 18 9 Pt 1 (2005) 1195-1199
27. Suzuki S., Wenyi Z., Hirai M., Hinokio Y., Suzuki C., Yamada T., et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25 10 (2004) 1803-1808
28. Thanassoulis G., Huyhn T., and Giaid A. Urotensin II and cardiovascular diseases. Peptides 25 10 (2004) 1789-1794
29. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 3 (2003) 246-253
30. Wang X., Ren B., Liu S., Sentex E., Tappia P.S., and Dhalla N.S. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol 94 2 (2003) 752-763